{"url_path":"/sec/tvtx/8-k/2026-07-09/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-09","source_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000054-index.html","accession_number":"0001438533-26-000054","cik":"0001438533","ticker":"TVTX","issuer_name":"Travere Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1438533/0001438533-26-000054-index.html","primary_entity_key":"0001438533","primary_entity_name":"Travere Therapeutics, Inc."},"word_count":500,"has_tables":true,"body_markdown":"Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.\n\n5.02(b)\n\nOn July 6, 2026, Sandra Calvin, chief accounting officer (CAO) and principal accounting officer (PAO) of the Company, provided notice to the Company of her intention to retire from employment with the Company following the filing of the Company’s Annual Report on Form 10-K expected in February 2027 (the “Retirement Date”). The Company expects John Torell, CFA, CPA, the Company's Vice President, Controller, to succeed Ms. Calvin as CAO and PAO. The Board of Directors is expected to appoint Mr. Torell to those roles in advance of the Retirement Date to facilitate an orderly transition of responsibilities.\n\nSince joining the Company in 2021, Mr. Torell, has been responsible for accounting operations, financial reporting, SEC reporting, technical accounting, and internal controls over financial reporting and has served as Vice President, Controller since 2023. From 1997 to 2019, Mr. Torell held positions of increasing responsibility within the finance organizations at Pacific Life Insurance Company, including serving as Vice President, Controller; Vice President, Assistant Controller; and Vice President of Finance, Investment Management Division. Earlier in his career he was an Audit Manager with Deloitte. Mr. Torell is a Chartered Financial Analyst, a Certified Public Accountant and holds a B.A. in Economics-Business from the University of California, Los Angeles.\n\nForward-Looking Statements\n\nThis report contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “on-track,” “positioned,” “look forward to,” “will,” “would,” “may,” “might,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: statements and expectations regarding the planned retirement of Ms. Calvin, the transition plan for the CAO/PAO role, and the timing thereof. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks related to human capital and the Company’s business needs and resources. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties, including under the heading “Risk Factors”, as included in the Company’s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission.\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n    TRAVERE THERAPEUTICS, INC.\n\n    \n\nDated: July 9, 2026   By:/s/ Eric Dube\n\n      Name:Eric Dube\n\nTitle:Chief Executive Officer"}